Development of an Atmospheric Plasma Applicator to Treat Chronic Wounds

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,188,490.00
Award Year:
2013
Program:
SBIR
Phase:
Phase II
Contract:
2R44GM099207-02
Award Id:
n/a
Agency Tracking Number:
R44GM099207
Solicitation Year:
2013
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA12-088
Small Business Information
231 Sam Rayburn Parkway, Lenior City, TN, 37771-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
24109418
Principal Investigator:
KIMBERLY KELLY-WINTENB
(865) 317-1425
kwintenb@advancedplasmaproducts.com
Business Contact:
KIMBERLY WINTENBERG
(865) 777-3776
kwintenb@advancedplasmaproducts.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Annually, 5 to 7 million Americans are treated for chronic wounds that arise from diabetes, lower extremity arterial disease, lower extremity venous disease, pressure ulcers, and traumatic injuries, including burns, demonstrating the need for new advanced technologies for treatment. Advanced Plasma Products will build upon its successful Phase I results and advance the development of the Atmospheric Plasma Wound Applicator (APWA) prototypes that inactivate biofilm without causing damage to surrounding tissues, thereby healing the wound. The prototype will be tested for its wound disinfecting capabilities with in vitro wound biofilm models of different clinically significant strains and polymicrobial biofilm. Penetration studies will be performed to evaluate the depth of plasma active species in tissue and mechanistic studies will evaluate the mechanism of inactivation of microbial cells by plasma treatment. We will demonstrate the therapeutic potential of atmospheric plasma to improve wound healing by the removal of microorganisms from the biofilm of splinted excisional wounds of normal and diabetic mice and the introduction of various gaseous nitrogen species. A second generation prototype will be built and tested in a clinical setting with equine lower limb wounds. Following this two year effort, APP will initiate FDA 510K regulatory approval process. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Public Health Impact Statement Chronic wounds affect 5 to 7 million Americans annually and generate healthcare cost in the billions of dollars. More importantly, chronic wounds contribute significantly to the mortality of patients in the United States, and lead to over 80,000 amputations annually due to complicationsin diabetic and peripheral arterial disease patients. Most chronic wounds are treated by outpatients wound care center requiring weekly visits and can take months to years to heal at high costs. The health-related quality of life of patients suffering fromchronic wounds is similar to that of patients wih recurrent cancer. There is an increase in lack of mobility and patients feel isolated and the incidence of depression is significantly higher than the general population. Since many chronic wound patientsare 65 years of age or older and covered by Medicare or Medicaid, there is a push to look at lower-cost alternative treatment technologies. Building upon our expertise in disinfection/sterilization of sensitive items, APP is meeting this demand to effectively treat chronic wounds by developing an Atmospheric Plasma Applicator using its patented atmospheric plasma technology.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government